ライフサイエンスコーパス: anti-DNA antibody

1 /c mice transgenic for the heavy chain of an anti-DNA antibody.

2 ur hospital because of a high serum level of anti-DNA antibody.

3 ansgenic for the heavy chain of a pathogenic anti-DNA antibody.

4 ansgenic for the heavy chain of a pathogenic anti-DNA antibody.

5 ibrosis, deforming arthropathy and increased anti-DNA antibodies.

6 D-deficient 3H9 mice spontaneously generated anti-DNA antibodies.

7 for research and point-of-care monitoring of anti-DNA antibodies.

8 mice) treated with pathogenic, noncomplexed anti-DNA antibodies.

9 ly on DNA-derived peptides and peptides from anti-DNA antibodies.

10 eptor is recognized by both murine and human anti-DNA antibodies.

11 ypocomplementemia, and/or elevated levels of anti-DNA antibodies.

12 ed transgenic mice whose transgenes code for anti-DNA antibodies.

13 adequate predictors of the pathogenicity of anti-DNA antibodies.

14 munosorbent assay plates was used to measure anti-DNA antibody activity.

15 c recipients caused a lupuslike disease with anti-DNA antibodies, an immune complex glomerulonephriti

16 Both human monoclonal anti-DNA antibodies and antibodies affinity purified fro

17 plus bromocriptine led to reduced titers of anti-DNA antibodies and diminished IgG deposition in kid

18 nctional because it helps B cells to produce anti-DNA antibodies and express more CD80 (B7-1) on thei

19 These mice develop high-titer anti-DNA antibodies and immune complex-mediated nephriti

20 antation (PBSCT) prevented the production of anti-DNA antibodies and the development of lupus nephrit

21 e received injections of radiolabeled murine anti-DNA antibody, antibody with no DNA binding capabili

22 We found that high-affinity anti-DNA antibodies are a major component of the intrath

23 Anti-DNA antibodies are associated with glomerulonephrit

24 Anti-DNA antibodies are produced transiently, mainly dur

25 Anti-DNA antibodies are regulated in normal individuals

26 Significant gene up-regulation induced by anti-DNA antibodies as determined by microarray analysis

27 ficantly reduced the renal deposition of the anti-DNA antibody at 48 h (1.53%, P < 0.00001) and at 7-

28 e c-erbB2 gene product, was recognized by an anti-DNA antibody, B3, and importantly by two classical

29 antibody could provide a mechanism by which anti-DNA antibodies bind diverse host ligands, and there

30 lowing recent reports that pathogenic murine anti-DNA antibodies bind to alpha-actinin, it was obviou

31 duction of IgM, IgG, and IgA, as well as IgM anti-DNA antibodies, but was not necessary for B cell st

32 It has been shown that anti-DNA antibodies cross-react with bacterial polysacch

33 A unique subset of anti-DNA antibodies enters living cells, interacts with

34 The anti-DNA antibody fragment 3E10 Fv has received attentio

35 itopes in the heavy chain variable region of anti-DNA antibodies from lupus-prone (NZB/NZW F1) mice.

36 ought to be correlated to the Arg content of anti-DNA antibody hypervariable loops.

37 pacity to quantify over the course of 30 min anti-DNA antibodies in fresh human serum without backgro

38 ing lower concentrations of DNA complexed to anti-DNA antibodies in human serum, we found a maximal e

39 ed levels of all immunoglobulin isotypes and anti-DNA antibodies in serum.

40 Deposition of anti-DNA antibodies in the kidney contributes to the pat

41 iolabeled antibody to evaluate deposition of anti-DNA antibody in the kidney and the successful use o

42 otects mice from renal deposition of the R4A anti-DNA antibody in vivo.

43 reated mice express high-affinity, unmutated anti-DNA antibodies, indicating that naive B cells that

44 found that treatment of mesangial cells with anti-DNA antibodies induced high expression of neutrophi

45 isting of the single chain Fv fragment of an anti-DNA antibody known to penetrate into living cells a

46 onitor patients with RA, 92% used either the anti-DNA antibody level or complement C3 level to monito

47 NA antibody-producing B cells, reduced serum anti-DNA antibody levels, retarded the development of ne

48 ertook this study to determine if pathogenic anti-DNA antibodies may also contribute to renal damage

49 ngs indicate that the renal pathogenicity of anti-DNA antibodies may be attributed in part to their a

50 ata suggest that a significant proportion of anti-DNA antibodies may cross-react with renal antigens

51 Our findings indicate that anti-DNA antibodies may promote important neuropathologi

52 The mechanism by which anti-DNA antibodies mediate lupus nephritis has yet to b

53 Anti-DNA antibodies often play an important role in dise

54 s for fluorescently stained eDNA with either anti-DNA antibodies or an ultrasensitive cell-impermeant

55 Specifically, no patient developed anti-DNA antibody or muscle enzyme elevations.

56 were no changes in serum levels of IgG, IgG anti-DNA antibodies, or V(H)4-34 antibodies during the s

57 The structural underpinnings of anti-DNA antibody pathogenicity and antibody-DNA recogni

58 Anti-DNA antibodies play important roles in the pathogen

59 arkedly reduced the frequency of IgG and IgG anti-DNA antibody-producing B cells, and these changes p

60 epitopes induced CD8(+) T cells that killed anti-DNA antibody-producing B cells, reduced serum anti-

61 NZB/NZW F1 mice and evaluated the effect on anti-DNA antibody-producing B cells.

62 olished key disease manifestations including anti-DNA antibody production and glomerulonephritis.

63 ived nucleic acids stimulates interferon and anti-DNA antibody production in SLE.

64 n complexes and autoreactive T-cell help for anti-DNA antibody production suggest novel directions fo

65 ges, and its levels inversely correlate with anti-DNA antibody response.

66 cant increase in the number of high-affinity anti-DNA antibody-secreting B cells in the spleens of E(

67 after treatment, and the frequency of Ig and anti-DNA antibody-secreting B cells was analyzed by enzy

68 ach of 3 patients, and a 10-fold decrease in anti-DNA antibody-secreting cell lines was found after t

69 toimmune liver disease and greater titers of anti-DNA antibodies than did males, and 2-7 times more c

70 Significantly higher renal deposition of anti-DNA antibody than of antibody without DNA binding c

71 f concept, we address a problem of detecting anti-DNA antibodies that are characteristic of systemic

72 ith mixed TCDM also reduced the formation of anti-DNA antibodies that are observed typically in male

73 SLE patients produce anti-DNA antibodies that crossreact with NMDA receptors

74 h mixed TCDM also prevented the formation of anti-DNA antibodies that is typically observed in male m

75 the heavy chain of a potentially pathogenic anti-DNA antibody that antibody affinity for dsDNA does

76 eact with R4A, a pathogenic mouse monoclonal anti-DNA antibody that deposits in glomeruli.

77 transgene-expressing B cells, elevated serum anti-DNA antibody titers, and glomerular immunoglobulin

78 temic lupus erythematosus, recent studies of anti-DNA antibody transgenic mice clearly demonstrate th

79 e as compared with (+/+) mice, but levels of anti-DNA antibodies were comparable in all groups.

80 athway inhibitor were injected into mice and anti-DNA antibodies were measured by enzyme-linked immun

81 Moreover, anti-DNA antibodies with this cross-reactivity mediate a